イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - carbidopa monohydrate; levodopa - modified-release tablet - 25mg ; 100mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - carbidopa monohydrate; levodopa - modified-release tablet - 25mg ; 100mg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: indigo carmine; hypromellose; hyprolose; allura red ac; magnesium stearate - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr in patients who have not been treated with levodopa before.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

ltt pharma limited - levodopa, carbidopa - tablets - 25/100 milligram - dopa and dopa derivatives

シンガポール - 英語 - HSA (Health Sciences Authority)

organon singapore pte. ltd. - carbidopa; levodopa - tablet - 50 mg - carbidopa 50 mg; levodopa 200 mg

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - tolcapone 100mg - film coated tablet - 100 mg - active: tolcapone 100mg excipient: calcium hydrogen phosphate ethylcellulose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc   sodium laurilsulfate sodium starch glycolate titanium dioxide triacetin - tasmar is indicated for use in combination with levodopa/benserazide and levodopa/carbidopa in parkinson's disease, including both fluctuating and non-fluctuating patients.

カナダ - 英語 - Health Canada

apotex inc - carbidopa; levodopa - tablet - 25mg; 250mg - carbidopa 25mg; levodopa 250mg - dopamine precursors

カナダ - 英語 - Health Canada

merck canada inc - levodopa; carbidopa - tablet (extended-release) - 100mg; 25mg - levodopa 100mg; carbidopa 25mg - dopamine precursors

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

merck sharp & dohme corp. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - sinemet cr is indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with sinemet cr. these inhibitors must be discontinued at least two weeks prior to initiating therapy with sinemet cr. sinemet cr may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions). sinemet cr is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: hyprolose; magnesium stearate; ferric oxide; va/crotonates copolymer; quinoline yellow aluminium lake - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr 200/50 in patients who have not been treated with levodopa before.